1157.8500 23.70 (2.09%)
NSE Apr 02, 2025 15:31 PM
Volume: 1.0M
 

1157.85
2.09%
KRChoksey
Aurobindo Pharma’s revenue beat our estimates (+2.8%) due to strong performance in Europe and Growth markets. EBITDA beat our estimates (+4.4%) due to better than expected gross profit and Adj. PAT beat our estimates due to better than expected other income and lower than expected tax expense.
Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1145.1
More from Aurobindo Pharma Ltd.
Recommended